CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jeffrey E LancetBruno C Medeiros

Abstract

Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and p...Continue Reading

References

Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanArthur C Louie
Mar 16, 2012·The New England Journal of Medicine·Matthew J WalterTimothy A Graubert
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jerzy HolowieckiOlga Haus
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roelof WillemzeTheo de Witte
Jan 1, 2015·Blood·R Coleman LindsleyBenjamin L Ebert
Mar 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M StoneBayard Powell
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daisuke ArakiRoland B Walter
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner

❮ Previous
Next ❯

Citations

Oct 3, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hetty E Carraway
Oct 27, 2018·Current Treatment Options in Oncology·Rebecca Levin-EpsteinGary Schiller
Dec 27, 2018·Current Opinion in Hematology·Charles Craddock, Manoj Raghavan
Dec 27, 2018·Current Opinion in Hematology·Anna B HalpernElihu H Estey
Dec 27, 2018·Current Opinion in Hematology·Tsila Zuckerman, Jacob M Rowe
Feb 5, 2019·Current Oncology Reports·Marco Cerrano, Raphael Itzykson
Jan 24, 2019·Expert Review of Clinical Pharmacology·Juan Eduardo Megías-VericatPau Montesinos
Jan 24, 2019·Blood·Uwe Platzbecker
Feb 19, 2019·Journal of Medical Economics·Louis S MatzaKaren C Chung
Mar 13, 2019·Genes, Chromosomes & Cancer·Ing S Tiong, Andrew H Wei
Dec 7, 2018·Hematology·Laura C Michaelis
Apr 25, 2019·Journal of Hematology & Oncology·Yaxian KongHong Zheng
Apr 5, 2019·American Journal of Hematology·Bruno C MedeirosDaniel A Pollyea
May 29, 2019·Expert Opinion on Pharmacotherapy·Minas P EconomidesNaveen Pemmaraju
Jan 18, 2019·Leukemia & Lymphoma·Jan Philipp BewersdorfAmer M Zeidan
Jun 5, 2019·Leukemia & Lymphoma·Marco CerranoDario Ferrero
Jun 5, 2019·Expert Review of Hematology·Jan Philipp BewersdorfAmer M Zeidan
Jun 15, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Martin S TallmanNdiya Ogba
Oct 1, 2019·British Journal of Haematology·Pierre FenauxLionel Ades
Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh
Oct 16, 2019·Expert Opinion on Investigational Drugs·Daniel J Lee, Joshua F Zeidner
Sep 25, 2019·Leukemia & Lymphoma·Mansour AlfayezNaval Daver
Sep 20, 2019·Journal of Hematology & Oncology·Catherine LaiKelly Norsworthy
Dec 13, 2019·British Journal of Haematology·Shilpa PaulElias J Jabbour
Dec 22, 2019·British Journal of Haematology·Caspian Oliai, Gary Schiller
Jan 11, 2020·Current Opinion in Hematology·Hannah Asghari, Chetasi Talati
Feb 12, 2020·Biomolecules·Edina WangAnabel Sorolla
Apr 3, 2020·American Society of Clinical Oncology Educational Book·Kristin KoenigMary M Horowitz
Apr 28, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Daniel R ReedMichael K Keng
May 1, 2020·British Journal of Haematology·Avraham FrischYishai Ofran
Mar 1, 2020·American Journal of Hematology·Guillermo Montalban-BravoTapan M Kadia

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
biopsy

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.